Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 8

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 8
---
 | KEY INFORMATION |

| A. | [Reserved] |

| B. | Capitalization and Indebtedness |

Not applicable.

| C. | Reasons for the Offer and Use of Proceeds |

Not applicable.

| D. | Risk Factors |

Our business is subject to a number of risks. You should carefully consider all of the information set forth in this Annual Report and in other documents we file with or furnish to the U.S. Securities and Exchange Commission, or SEC, including the following risk factors, before deciding to invest in or to maintain an investment in our securities. Our business, as well as our reputation, financial condition, results of operations, and share price, could be materially adversely affected by any of these risks, as well as other risks and uncertainties not currently known to us or not currently considered material. Risk Factors Summary Our ability to implement our business strategy is subject to numerous risks, as more fully described in this section. These risks include, among others:

| • | We are a clinical-stage biopharmaceutical company and we have incurred significant losses since our inception. We expect that we will continue to incur significant losses for the foreseeable future; |

| • | We will need substantial additional funding, which may not be available on acceptable terms, or at all. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development 
 programs or commercialization efforts;                                                                                                                                                                                                        |

1 Table of Contents

| • | Preliminary, top-line or interim data from our clinical trials that we announce or publish from time to time may change as more data become available, and are subject to audit and verification procedures that could result in material 
 changes in the final results or could otherwise harm our business, financial condition, results of operation and prospects;                                                                                                               |

| • | It may take considerable time and expense to resolve the clinical hold that has been placed by the FDA on the study we proposed in our IND for GH001, and no assurance can be given that the FDA will remove the clinical hold, which could 
 have a material adverse effect on our clinical development efforts or could otherwise harm our business, financial condition, results of operation and prospects;                                                                           |

| • | Drug and drug-device combination product development is a highly uncertain undertaking and involves a substantial degree of risk; |

| • | GH001 and GH002 are investigational mebufotenin therapies based on a novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory